Drug NSAIDs DMARDs Opioids Steroids Substrate Inhibitor Inducer Aspirine X       2C8, 2C9   2C19 Diclofenac X       2C8, 2C9, 2C19, 3A4, 2C8, 2C9, 3A4   Ibuprofen X       2C8, 2C9, 2C19 2C9   Indometacine X       2C9, 2C19 2C9, 2C19   Ketoprofen X         2C9, 2C10   Metamizol X           2B6, 3A4 Naproxen X       1A2, 2C8, 2C9     Oxaprozin X       2C9     Paracetamol X       1A1, 1A2, 2A6, 2C8, 2C9, 2D6, 2E1, 3A4 3A4 2D6, 2E1, 3A4/5 Phenylbutazon X       2C9   3A4 Piroxicam X       2C9 2C9   Betamethasone       X 19A 3A4 19A Hydrocortisone       X 3A4 3A4 2C8, 3A4 Prednisone       X 3A4 3A4 1A1, 1A2, 3A4 Codeine     X   2D6, 3A4 2D6   Fentanyl     X   3A4 3A4   Morphin     X   2C8, 3A4     Tramadol     X   2B6, 2D6, 3A4 2D6, 3A4   Chloroquine   X     1A1, 2C8, 2D6, 3A4 2D6   Cyclosporine   X     3A4 2C19, 2D6, 3A4   Hydochloroquine   X       2D6   Leflunomide   X     2C8, 2C9 2C8, 2C9   Additional administration of antibiotics in the therapy of PD could influence the metabolism of the other drugs administered for RA therapy. Potent antibiotic agents against periodontal bacterial pathogens are listed in Table

Table 1: Drugs in the therapy of RA with CYP metabolism. Involved CYPs are ordered in mode of action (substrate, inhibitor, inducer) and references are given in supplementary material.